Managers / Q4 2024 · view latest →
BIOS Capital Management, LP
CIK 0001813845 · 1751 RIVER RUN, SUITE 400, FORT WORTH, TX, 76107 · 817-984-9197
Summary
Bios Capital Management, LP reported $94M in U.S.-listed holdings across 9 positions for Q4 2024.
The portfolio is heavily concentrated: ACTU alone accounts for 72.0% of reported value.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $94M
Quarter-over-Quarter Changes full breakdown →
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ACTUACTUATE THERAPEUTICS INC | NEW | +9.89M | 9.89M | +$79M | $79M |
| CGTXCOGNITION THERAPEUTICS INC | NEW | +6.00M | 6.00M | +$4M | $4M |
| RNTXAILERON THERAPEUTICS INC | NEW | +1.69M | 1.69M | +$4M | $4M |
| LTRNLANTERN PHARMA INC | NEW | +1.21M | 1.21M | +$4M | $4M |
| INABEURIN8BIO INC | NEW | +8.60M | 8.60M | +$2M | $2M |
| IRDOPUS GENETICS INC | NEW | +995.2K | 995.2K | +$1M | $1M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ACTUACTUATE THERAPEUTICS INChistory → | COM | 83.69% | $79M | 9.89M |
| 2 | CGTXCOGNITION THERAPEUTICS INChistory → | COM | 4.47% | $4M | 6.00M |
| 3 | RNTXAILERON THERAPEUTICS INChistory → | COM NEW | 4.13% | $4M | 1.69M |
| 4 | LTRNLANTERN PHARMA INChistory → | COM | 4.09% | $4M | 1.21M |
| 5 | INABEURIN8BIO INChistory → | COM | 2.35% | $2M | 8.60M |
| 6 | IRDOPUS GENETICS INChistory → | COM | 1.26% | $1M | 995.2K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $53M | 10 | May 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $83M | 9 | Feb 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $89M | 9 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $73M | 9 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $79M | 9 | May 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $94M | 9 | Feb 18, 2025 | RESTATEMENT | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- Steelhead Capital Management, LLC
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.